Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval

Submitted by admin on January 19, 2023 - 10:15am

Source:

Motley Fool

News Tags:

Headline:

snippet:

Biogen investors have been here before: an Alzherimer's treatment that obtains authorization but still isn't fully approved.
Investors are more cautious this time around, as is clear from the lack of upward movement in the stock's share price.
Declining revenue means Biogen needs a big catalyst to get its shares moving.

Search form